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Abstract
Community-acquired pneumonia (CAP) due to Streptococcus pneumoniae still occurs in at risk
populations, despite the availability of effective vaccines. Laboratory confirmation of S. pneumoniae
remains challenging in cases of CAP despite advances in blood culture techniques and the
availability of nucleic acid amplification tests such as PCR-based methods. Urine specimens are an
attractive sample type because they are non-invasive compared to bronchial washes or whole blood
specimens for patients with CAP. While urine specimens have been used successfully in antigen
detection assays, they have not been extensively evaluated for PCR-based assays. In this preliminary
study, we evaluated the potential for a real-time PCR assay targeting the S. pneumoniae autolysin
gene (lytA) to detect in archived urine samples from patients with CAP. Results indicate that the real
time lytA PCR assay on the Luminex ARIES® system shows promise as a screening tool for patients
with CAP based on comparison to urine antigen detection assay results.
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Introduction

shortness of breath, malaise and weakness may follow [7].

Streptococcus pneumoniae is an encapsulated, Gram-positive
coccoid shaped, facultative anaerobic bacterium. In addition,
S. pneumoniae is alpha-hemolytic under aerobic conditions
and beta-hemolytic under anaerobic conditions. It can be
distinguished from other Streptococcus species using optochin
and bile susceptibility tests, although there are exceptions. The
organism is somewhat fastidious, and thus only 20-30% of
pneumococcal pneumonia cases are blood culture positive [1, 2].
Due to its fastidious nature and other factors, such as autolysin
production in the stationary growth phase [3, 4], culture
remains difficult. There are 90 serotypes of S. pneumoniae, but
a much smaller subset of these cause significant human disease,
making vaccine development a successful endeavor in reducing
disease in at-risk populations [5, 6].

Complications of pneumococcal pneumonia include empyema,
pericarditis and respiratory failure. According to the most recent
2013 Active Bacterial Core Surveillance (ABCs) Report from the
CDC’s Emerging Infections Program Network [8],
S. pneumoniae was the cause of 69.1% of cases of pneumonia
with bacteremia; 16.7% of cases of bacteremia (with no focus);
and 6.4% of cases of meningitis based on a survey population
of over 30 million people. In this population-based survey,
invasive S. pneumoniae in children <4 years of age comprised
6.42% of all cases and adults >65 years of age comprised 37.5%
of all cases [8].

The CDC states that there are 400,000 hospitalizations per
year in the US, and 36% of Community-acquired pneumonia
is due to pneumococcus [7]. Of these cases, 25-30% become
bacteremic, with an overall mortality rate of 5-7% [7]. Adults
most commonly present with pneumonia after a brief one to
three-day incubation period. After an abrupt onset of fever and
chills, other symptoms such as chest pain, productive cough,
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Since the year 2000, polyvalent vaccines that cover 7, 13 or 23
different serotypes have been used to protect the most vulnerable
populations. The pneumococcal conjugate vaccine (PCV13) is
administered as a series for children under two years of age and
adults 65 years and older [9]. The pneumococcal polysaccharide
vaccine (PPSV23) is recommended for adults age 65 years and
older, as well as anyone two years old and above at high risk of
disease [9]. Persons who are immunocompromised, smoke or
have asthma, are also candidates for these vaccines. While the
introduction of vaccines that protect against multiple common
S. pneumoniae serotypes has reduced pneumococcal disease
significantly, cases still occur. Invasive pneumococcal disease is
on the national notifiable diseases list, as well as the Kentucky

ULJRI Vol 1, (4) 2017

19

Reportable Diseases and Conditions list, and tracking drug
resistance patterns remains important. As of 2013, the ABCs
report indicated that among 2898 isolates of S. pneumoniae,
2.2% were resistant to penicillin, 28.2% were resistant to
erythromycin and 10.3% were resistant to tetracycline [8].
Laboratory diagnosis remains challenging for S. pneumoniae,
however. Available diagnostic testing methods fall into three
major categories at this time, including microscopy with
microbiological culture, urine antigen detection assays and
molecular testing such as PCR on cerebrospinal fluid (CSF),
sputum or whole blood; however, no gold standard has been
agreed upon. Molecular diagnostic testing is attractive, due to
increased speed and sensitivity. One promising PCR target is
the lytA gene of S. pneumoniae because the lytA gene is specific
to S. pneumoniae [1]. This gene encodes a well-documented
virulence factor and has little genetic variation within the
species [10].
While lytA has been published as a promising PCR target for
whole blood, sputum, serum samples, middle ear fluid and
CSF specimen types [1, 2], it has not been tested extensively
on urine samples. Our aim was to assess the feasibility of fully
validating a rapid and sensitive PCR assay on the Luminex
ARIES® platform using a non-invasive specimen type in order
to detect S. pneumoniae from patients with a clinical diagnosis
of pneumonia. The design of this study was to use archived urine
samples from hospitalized patients with Community-acquired
pneumonia (CAP) [11] for PCR analysis using the lytA gene
target with Multicode® primers. Because previous laboratory
results were available for these cases, the selected urine samples
were either from patients with S. pneumoniae blood culture
positive results or from patients, who by laboratory analysis,
were negative for S. pneumoniae. In addition, urine samples
from healthy volunteers were used as negative controls for
this study. Preliminary results are promising for this assay and
warrant further research and development.

Methods and Materials
Archived Urine Specimens: Sixty archived urine specimens
were obtained from the University of Louisville Respiratory
Biorepository in the Division of Infectious Diseases. Urine
specimens selected for this study were collected between 20142016 [11]. Briefly, the original urine samples from patients
hospitalized with Community-acquired pneumonia (CAP) were
held at 4°C, then processed within 28 hours of collection by
adding 0.5 mL of 0.5M PIPES buffer (VWR, Radnor, PA, Part
Number BB-121-250 mL) to 9.5 mL of urine. After mixing well,
aliquots were frozen at -80°C in the Biorepository until thawed
once for lytA PCR and BinaxNOW® S. pneumoniae antigen card
testing. Aliquots of 200 μL of archived urine samples were used
from 30 pneumococcus negative patients (having no laboratory
evidence of Streptococcus pneumoniae infection) and 30
patients having Streptococcus pneumoniae blood culture
positive results.
Fresh Urine Specimens (Negative Controls): An additional 30
fresh urine samples were collected from healthy volunteers.
These urine samples were collected and stored at 4°C less
than 28 hours prior to processing by adding 0.5 mL of 0.5M
PIPES buffer to 9.5 mL of urine. They were tested first after
refrigerating, and again after freezing once at -20°C for 1-4

weeks, with no change in lytA PCR or BinaxNOW® test results.
ARIES® Instrument, ReadyMix®, Cassettes and PCR Analysis:
The universal thermal profile settings on the ARIES®
instrument were used for PCR. Cassettes (Part Number 5010026) and ReadyMix® (Part Number 3697) were purchased
from Luminex (Austin, TX). The ARIES® software automatically
generated the amplification and melt curves and assigned the
corresponding cycle threshold (Ct) and melting temperature
(Tm) values. Specimens were considered positive only if lytA
and the specimen processing control Mouse Hepatitis Virus-2
(MHV2) were detected in the Ct and Tm ranges established for
this assay (see Table 1). A sample was called “Invalid” if the
MHV2 amplification failed.
Reagents: MultiCode® primer pairs for the Streptococcus
pneumoniae lytA gene were obtained from Integrated DNA
Technologies, Inc. (Coralville, IA). The MultiCode® primer
sequence for lytA forward primer is /56-FAM//iMe-isodC/A
CGC AAT CTA GCA GAT GAA GCA and the reverse primer is
CTC CCT GTA TCA AGC GTT TTC GGC, based on a previous
publication [1]. The MHV2 primer set (proprietary primer
sequences, Luminex, Part Number 3803) was used as the sample
processing control (SPC) in order to confirm that PCR inhibitors
were not present. Furthermore, melt curve (Tm) data allows for
calibration of detected melting temperatures for both lytA and
MHV2 PCR amplifications. The lytA primer set was assigned
to the FAM channel and MHV2 primer set was assigned to the
AP525 channel.
Primer Pool Preparation: 50 μL of 5 µM lytA forward primer,
50 μL of 5 µM lytA reverse primer and 100 μL of MHV2 primer
set were mixed together. Frozen aliquots of the primer mix
were stored at -20°C. From these aliquots, 4 μL of the primer
pool (giving a final concentration of 200 nM) were used per
ReadyMix® vial.
Control Material: Titered Streptococcus pneumoniae
(ZeptoMetrix, Buffalo, NY, Part Number 0801439) was
purchased and used for accuracy and analytical sensitivity
studies by diluting it in negative urine specimens at various
concentrations. Urine samples were screened by the
BinaxNOW® S. pneumoniae antigen card and lytA PCR assay
prior to use to ensure specimens were negative by both methods.
Analytical Sensitivity and Precision: For analytical sensitivity,
the limit of detection (LOD) was determined for the lytA target
using titered S. pneumoniae in negative urine (screened by
BinaxNOW® S. pneumoniae antigen card and lytA PCR assay).
S. pneumoniae was spiked into negative urine specimens using
0.2 mL aliquots per cassette at 1 x 103 CFU/mL (200 CFU/
cassette), 1 x 102 CFU/mL (20 CFU cassette), 1 x 101 CFU/
mL (2 CFU/cassette), 1 x 100 CFU/mL (0.2 CFU/cassette), 1
x 10-1 CFU/mL (0.02 CFU/cassette), 1 x 10-2 CFU/mL (0.002
CFU/cassette) concentrations and tested. The LOD assay was
repeated three times, independently, to demonstrate inter-assay
precision as well as sensitivity.
Accuracy: For the accuracy study, 11 known negative urine
samples and 16 known positive samples, made up of various
concentrations of Streptococcus pneumoniae that were spiked
into negative urine (screened by BinaxNOW® S. pneumoniae
antigen card and lytA PCR assay). Samples were blinded and
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tested by staff members that did not prepare the accuracy panel.

Table 2 Streptococcus pneumoniae PCR LOD
Sample ID lytA Ct ±SD

Clinical Criteria
Invasive Pneumococcal (Streptococcus pneumoniae) Disease, or IPD, causes
many clinical syndromes, depending on the site of infection (e.g.,
bacteremia, meningitis.)
Laboratory Criteria for Diagnosis
Supportive: Identification of S. pneumoniae from a normally sterile body site
by a culture independent diagnostic test [CIDT] without isolation of the
bacteria.
Confirmatory: Isolation of S. pneumoniae from a normally sterile body site.

Table 1 ARIES lytA PCR Assay Conditions

1
2
3

Melt curve (Tm) peak
threshold Cutoff (DRFU)

S. pneumoniae
lytA
1-40.5

SPC MHV2

77.21-81.21
(±2 degrees of the
average)
-400,000

74.88±79.88
(±2 degrees of the
average)
-175,000

77.56±0.32

S. pneumoniae 100 CFU/mL 34.23±1.1

79.12±0.06

24.6±1.47

77.4+0.46

79.22±0.12

23.97±0.5

77.53±0.21

79.5

24.2±0.56

77.47±0.32

S. pneumoniae 0.1 CFU/mL

24.73±0.38

77.47±0.35

S. pneumoniae 0.01 CFU/mL

24.27±0.87

77.53±0.21

SD=Standard Deviation

Data Analysis: Mean and standard deviation were calculated
using Microsoft Excel. The MEDCALC Diagnostic Test Evaluation
tool was used to determine analytic sensitivity and
specificity [13]. Luminex SYNCT® software was used to analyze
the PCR data. The highest Ct value for an lytA true positive was
40.4, so the lytA target was set at 40.5 (Table 1). The mean of
the Tm for an lytA true positive was 79.21°C, and was used as the
melt curve window ± 2, and 20% of deepest Tm Δ RFU (change in
relative fluorescence units) was set as Tm peak threshold cutoff
(Table 1). The SPC MHV2 cutoff was set the same way as the S.
pneumoniae lytA. After completing PCR assay data analysis, cut
off values were fixed on the SYNCT® software (Table 1) assay file
and locked on the ARIES® instrument for subsequent specimen
testing.

Conditions

24±0.46

S. pneumoniae 1 CFU/mL 38.2

Box 1 Council of State and Territorial Epidemiologists
(CSTE) Case Definition [12]

Amplification curve (CT)
Cutoff
Melt curve (Tm) cutoff in
in °C

MHV2 Ct ±SD MHV2 Tm ±SD

79.25±0.1

S. pneumoniae 10 CFU/mL 37.13±1.63

Comments
The use of CIDTs as stand-alone tests for the direct detection of S.
pneumoniae from clinical specimens is increasing. Data regarding their
performance indicate variability in the sensitivity, specificity, and positive
predictive value of these assays depending on the manufacturer and
validation methods used. It is therefore useful to collect information on the
laboratory conducting the testing, and the type and manufacturer of the
CIDT used to diagnose each IPD case. Culture confirmation of CIDTpositive specimens is still the ideal method of confirming a case
of IPD.

S. No

lytA Tm ±SD

S. pneumoniae 1000 CFU/mL 30.4 ±0.44

1-45

Alere BinaxNOW® S. pneumoniae Antigen Card: For this study,
90 urine specimens were tested by BinaxNOW®, 30 from each
group described in “Specimens” section. Urine samples were
screened following the manufacturer’s instructions [14]. Briefly,
the swab provided with the Alere kit was dipped into the
urine specimen to be tested, the swab was placed in the
BinaxNOW® device, and three drops of reagent were added to
swab. Result was read at 15 minutes. Per the package insert (14),
the limit of detection if 105 cells/mL or 1:250 dilution of a known
positive patient urine.

Results
The analytical sensitivity for Streptococcus pneumoniae in urine
with this PCR assay was 10 CFU/mL. Results are represented in
Table 2 as mean ± standard deviation, calculated from three
independent experiments. No mean and standard deviation
were calculated for the 1 CFU/mL concentration, which was only
positive in one out of three runs (33%). Inter-assay precision, as
illustrated by the small standard deviations for Ct values and Tm
values (Table 2), was excellent. There was little variation among
three independent runs at the 1000 CFU/mL, 100 CFU/mL and
10 CFU/mL dilutions.

The accuracy of the assay was tested using a blinded panel
of negative urine samples spiked with known quantities of S.
pneumoniae. There were no false negative results, but one
apparent “false” positive result. This was from a sample spiked
with 1 CFU/mL, which is below the established LOD, but S.
pneumoniae was present in sample. We found that this level
could be detected 33% of the time (Table 2). Based on results
shown in Table 3, the sensitivity was 100% [95% Confidence
Interval (CI) 79.41% to 100%] and the specificity was 90.91%
(95% CI 58.71% to 99.77%).
Table 3 Accuracy of lytA PCR Assay in Urine Spiked with S. pneumoniae
lytA Detection by PCR Observed Positive Observed Negative
Expected Positive (16) 16

0

Expected Negative (11) *1

10

The performance of the lytA PCR assay was compared to the
BinaxNOW® S. pneumoniae urine antigen test using clinical
samples (Table 4). These 90 clinical samples consisted of
three different groups as indicated in Table 4. Archived urine
samples from patients with CAP, but no laboratory evidence of S.
pneumoniae infection, were tested with the lytA PCR assay and
the BinaxNOW® S. pneumoniae assay. This group was comprised
of 16 females (53.3%) and 14 males (46.7%) with an average age
of 60.7 years (range 31-81 years old). Three (3) samples were lytA
PCR positive out of 30 negative urine sample tests, giving a 10%
PCR positivity rate for S. pneumoniae on this sample set (Table
4). No inhibition was observed based on MHV2 Ct values and Tm
data. BinaxNOW® S. pneumoniae antigen results for this clinical
sample was 100% negative (30/30) (Table 4), which gave the
lytA PCR assay a 90% specificity (95% CI 73.47% to 97.8%). A
second set of archived urine samples from patients with CAP who
were blood culture positive for S. pneumoniae were also tested
by lytA PCR and BinaxNOW®. This group was comprised of 15
females (50%) and 15 males (50%), with an age range of 20 to 100
years old (average 63.5 years). Of this group, 13 out of 30 urine
samples were lytA positive by PCR, giving a 43.3% positivity
rate for this sample set (Table 4). No inhibition was observed
bazsed on MHV2 Ct and Tm data. BinaxNOW® S. pneumoniae
urine antigen results for this sample set was 83.3% in agreement
(25/30 total results) with ] the lytA PCR assay (Table 4). It is
interesting to note that there were five (16.7%) discrepant results
(3 lytA PCR positive, but BINAX NOW negative; 2 lytA PCR
negative, but BINAX NOW positive). Comparing performance
of the lytA PCR assay to BinaxNOW® S. pneumoniae urine
antigen results for the blood culture positive group as the “gold
standard,” the sensitivity of the PCR assay was 85.71% (95%
CI 57.91% to 98.22%) while the specificity was 85.71% (95% CI
63.66% to 96.95%).
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Table 4 Clinical Urine Sample Summary Results
Group

lytA PCR

BinaxNOW®

lytA PCR

BinaxNOW® Negative

(n=30 for each)

Positive Results, n (%)

Positive Results, n (%)

Negative Results, n (%) Results, n (%)

CAP, no laboratory

3 (10)

0 (0)

27 (90)

30 (100)

13 (43.3)

12 (40)

17 (56.7)

18 (60)

0 (0)

0 (0)

30 (100)

30 (100)

evidence of S.
pneumoniae
CAP, blood culture
positive for S.
pneumoniae
Healthy volunteers

The final group of 30 urines tested by lytA PCR and BinaxNOW®
was from healthy volunteers consisting of 17 males (56.7%)
and 13 females (43.3%), with an age range of 23 to 65 years
old (average 34.6 years). None of these urine samples was lytA
positive or BinaxNOW® antigen positive (Table 4), which
gave the lytA PCR assay a 100% specificity. No inhibition was
observed based on MHV2 Ct values and Tm data.
Specificity studies were not done in this preliminary study due to
lytA PCR specificity data being available from three previously
published studies also using the lytA target used in this report.
Carvalho et al. [1] used an extensive strain collection from the
CDC Streptococcus Laboratory to assess specificity of the lytA
primer set. Carvalho demonstrated that using 5 ng/µL DNA
extracted from 67 strains, representing 44 different serotypes
of S. pneumoniae isolates, and 104 non pneumococcal isolates,
there was 100% specificity for S. pneumoniae. In another study
demonstrating specificity, Sheppard et al. [2] used a panel of
59 isolates including 18 species of streptococci and 21 other
closely related species or common pathogens and found no
crossreactivity with an lytA primer set. Finally, McAvin et al.
used 44 organisms from diverse genera and 26 negative control
organisms, including 7 Streptococcus species, and also observed
100% specificity with no cross-reactivity with an lytA PCR assay
[10].

Discussion
The goal of this preliminary study was to assess the feasibility of
fully validating the performance of an lytA PCR assay in urine
specimens from patients diagnosed with CAP [11] for use in a
future, prospective study. The lytA target was chosen due to
several publications indicating high specificity of the autolysin
gene for S. pneumoniae [1]. Using the Luminex ARIES®
platform that automates DNA extraction, PCR amplification and
real-time detection, we found that the MultiCode® lytA assay
could reliably detect 10 CFU/mL in urine. Accuracy studies
using negative urine samples spiked with known quantities of
S. pneumoniae demonstrated 16/16 (100%) lytA positive for
known positive samples and 10/11 (90.9%) lytA negative for
known negative samples. With archived clinical samples, we
observed 43.3% lytA positive urine samples from S. pneumoniae
blood culture positive CAP patients and 10% lytA positive urine
samples from CAP patients with no laboratory evidence of S.
pneumoniae infection. None of the urine samples from 30
healthy volunteers were positive for lytA. All 90 urine specimens
were tested by the BinaxNOW® S. pneumoniae antigen card test
as well as by PCR after one freeze-thaw cycle. The only group
with any positive BinaxNOW® S. pneumoniae antigen results
was the blood culture positive patients. The BinaxNOW® S.
pneumoniae antigen card did not perform as well as stated in
the package insert [14] in our study, however. The urine antigen
detection assay BinaxNOW® for S. pneumoniae has a stated

sensitivity of 86% and specificity of 94% [14] in adults, based
on a retrospective study of urine specimens from blood culture
positive patients. The package insert does not specify either the
length of time or freezer temperature storage conditions that
ensure the test results are valid for urine, thus it is possible that
long-term storage at -80°C affected assay performance. As noted
in our results, there were five discrepant results out of 30 CAP
patients with S. pneumoniae positive blood cultures, but overall
the two assays detected similar numbers of positive results in this
group (Table 4). Three of these were lytA positive with the lytA
PCR assay, but BinaxNOW® negative, while two patients were
lytA negative but BinaxNOW® positive. Another explanation
for the discrepant results (besides long-term storage at -80°C)
is that the targets of each assay are different (DNA versus
antigens). Further study of these patient specimens would be
required to truly understand these interesting differences,
as well as completing a prospective study with similar groups
using fresh urine specimens rather than long-term frozen urine
specimens.
To place these results in context of other standard laboratory
diagnostic tests, only 15-30% of patients with CAP due to S.
pneumoniae have positive blood cultures [1, 2]. While numerous
lytA PCR assays have been reported for use with multiple
specimen types, urine has not been evaluated extensively.
Whole blood was evaluated in one study for patients with either
pneumococcal septicemia or with pneumococcal pneumonia
with positive blood cultures [2]. For the septicemic patient
group, 51.7% of the whole blood specimens were lytA positive,
while for the pneumonia patient group, 39.5% were positive
[2]. Additional testing by this group found that for 105 blood
culture positive samples, 42.9% were positive for lytA [2]. This
is in contrast to 100% of CSF specimens, sputum specimens and
lung biopsy tissue giving positive results with the lytA PCR assay
[2]. In a study by Murdoch et al. [15], using the pseudolysin
(ply) gene instead of lytA, throat swabs and sputum specimens
demonstrated 55% and 81% PCR positivity, respectively. Results
for plasma, buffy coat and urine were 2% using the same ply
PCR assay [13].
Despite the findings of these previous studies, urine remains
an attractive specimen type due to its non-invasive collection
method for patients with CAP. Urine antigen assays are widely
used because they are rapid and perform well on adults [2]
despite the highly variable carriage rate in healthy adults
[5]. The BinaxNOW® S. pneumoniae urine antigen assay is
not recommended pediatric patients, however, due to welldocumented issues with S. pneumoniae nasopharyngeal
carriage in children [16]. The potential benefit of PCR assays
is the ability to quantify the amount of DNA present and to set
thresholds for carriage versus infection rates. Future studies
could address the utility of a quantitative PCR assay with urine
from children suspected of having streptococcal infections.
This preliminary study has some limitations. The first is that
only the lytA autolysin gene target was used for PCR analysis
in urine. Future studies may involve S. pneumoniae psaA
MultiCode primer sets, or other published gene targets specific
to S. pneumoniae, to serve as a confirmatory test after screening
positive with the lytA PCR assay. A second limitation is that
the urine samples were archived from patients hospitalized
with CAP, stored at -80°C since January 2014. Repeated freeze
thawing of certain sample types is known to reduce sensitivity of
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PCR assays and the effect of long term storage at -80°C on the
BinaxNOW® antigen test remains unclear. Specimen stability
experiments will need to be performed in a prospective study
to address these variables. Finally, the urine sample sizes are
small due to the availability of archived urine samples that
met the criteria established for this study (i.e. urine had to be
from patients with CAP having a positive blood culture versus
those patients having all negative laboratory results for S.
pneumoniae). If the preliminary data hold true when testing
additional urine from patients with CAP, then future studies
could be performed to validate other MultiCode® primers on the
ARIES® platform. Upon completion of the full validation study,
a cost comparison of the lytA PCR assay and the urinary antigen
test would be useful information. The potential to develop
MultiCode® primer sets to detect key antibiotic resistance
markers in addition to identifying Streptococcus pneumoniae
would be an advance in laboratory diagnostics for patients with
CAP.
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